Supplemental Figure S7 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

Supplemental Figure S7 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

<p>Supplemental Figure S7 shows clone family gene signature set expression at drug tolerance.</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Jennifer L. Cotton (17315204) (author)
Diğer Yazarlar:	Javier Estrada Diez (17315207) (author), Vivek Sagar (17315210) (author), Julie Chen (17315213) (author), Michelle Piquet (15460169) (author), John Alford (17315216) (author), Youngchul Song (17315219) (author), Xiaoyan Li (17315222) (author), Markus Riester (17315225) (author), Matthew T. DiMare (17315228) (author), Katja Schumacher (17315231) (author), Gaylor Boulay (17315234) (author), Kathleen Sprouffske (15099146) (author), Lin Fan (17315237) (author), Tyler Burks (17315240) (author), Leandra Mansur (17315243) (author), Joel Wagner (17315246) (author), Hyo-eun C. Bhang (17315249) (author), Oleg Iartchouk (17315252) (author), John Reece-Hoyes (17315255) (author), Erick J. Morris (17315258) (author), Peter S. Hammerman (17315261) (author), David A. Ruddy (15460166) (author), Joshua M. Korn (17315264) (author), Jeffrey A. Engelman (17315267) (author), Matthew J. Niederst (17315270) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Tumor Biology Therapeutic Research and Development Methods and Technology Drug Resistance Lung Cancer Single Cell Technologies Tumor Heterogeneity
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Supplemental Figure S1 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
Yazar:: Jennifer L. Cotton (17315204)
Baskı/Yayın Bilgisi: (2025)

Supplemental Figure S2 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
Yazar:: Jennifer L. Cotton (17315204)
Baskı/Yayın Bilgisi: (2025)

Supplemental Figure S3 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
Yazar:: Jennifer L. Cotton (17315204)
Baskı/Yayın Bilgisi: (2025)

Supplemental Figure S4 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
Yazar:: Jennifer L. Cotton (17315204)
Baskı/Yayın Bilgisi: (2025)

Supplemental Figure S5 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
Yazar:: Jennifer L. Cotton (17315204)
Baskı/Yayın Bilgisi: (2025)

Supplemental Figure S6 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
Yazar:: Jennifer L. Cotton (17315204)
Baskı/Yayın Bilgisi: (2025)

Supplemental Figure S8 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
Yazar:: Jennifer L. Cotton (17315204)
Baskı/Yayın Bilgisi: (2025)

Supplemental Tables 1 - 12 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
Yazar:: Jennifer L. Cotton (17315204)
Baskı/Yayın Bilgisi: (2025)

Figure 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
Yazar:: Robert L. Hollis (15034814)
Baskı/Yayın Bilgisi: (2025)

Figure 2 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
Yazar:: Robert L. Hollis (15034814)
Baskı/Yayın Bilgisi: (2025)

Figure 3 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
Yazar:: Robert L. Hollis (15034814)
Baskı/Yayın Bilgisi: (2025)

Figure 4 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
Yazar:: Robert L. Hollis (15034814)
Baskı/Yayın Bilgisi: (2025)

Figure 5 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
Yazar:: Robert L. Hollis (15034814)
Baskı/Yayın Bilgisi: (2025)

Table 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
Yazar:: Robert L. Hollis (15034814)
Baskı/Yayın Bilgisi: (2025)

File_S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Yazar:: Stéphane Fattori (15048281)
Baskı/Yayın Bilgisi: (2025)

Table S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Yazar:: Stéphane Fattori (15048281)
Baskı/Yayın Bilgisi: (2025)

Table S2 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Yazar:: Stéphane Fattori (15048281)
Baskı/Yayın Bilgisi: (2025)

Table S3 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Yazar:: Stéphane Fattori (15048281)
Baskı/Yayın Bilgisi: (2025)

Table S4 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Yazar:: Stéphane Fattori (15048281)
Baskı/Yayın Bilgisi: (2025)

Table S5 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Yazar:: Stéphane Fattori (15048281)
Baskı/Yayın Bilgisi: (2025)

Table S6 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Yazar:: Stéphane Fattori (15048281)
Baskı/Yayın Bilgisi: (2025)

Table S7 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Yazar:: Stéphane Fattori (15048281)
Baskı/Yayın Bilgisi: (2025)

Table S8 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Yazar:: Stéphane Fattori (15048281)
Baskı/Yayın Bilgisi: (2025)

Supplemental Tables 1-8 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated <i>SPP1</i><sup>+</sup> Macrophages and Fibroblasts
Yazar:: Anuja Sathe (15028097)
Baskı/Yayın Bilgisi: (2025)

Supplemental Table 1 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
Yazar:: Morten Lapin (15056728)
Baskı/Yayın Bilgisi: (2025)

Supplemental Table 2 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
Yazar:: Morten Lapin (15056728)
Baskı/Yayın Bilgisi: (2025)

Supplemental Table 3 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
Yazar:: Morten Lapin (15056728)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities
Yazar:: Yibin Dai (16374331)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities
Yazar:: Yibin Dai (16374331)
Baskı/Yayın Bilgisi: (2025)

Table S1 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
Yazar:: Guillaume Davidson (14964069)
Baskı/Yayın Bilgisi: (2025)

Table S2 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
Yazar:: Guillaume Davidson (14964069)
Baskı/Yayın Bilgisi: (2025)

Table S3 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
Yazar:: Guillaume Davidson (14964069)
Baskı/Yayın Bilgisi: (2025)

Table S4 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
Yazar:: Guillaume Davidson (14964069)
Baskı/Yayın Bilgisi: (2025)

Table S9 from Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer
Yazar:: Zhihang Chen (17315678)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table1 from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
Yazar:: Yidan Ren (14845140)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table2 from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
Yazar:: Yidan Ren (14845140)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table3 from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
Yazar:: Yidan Ren (14845140)
Baskı/Yayın Bilgisi: (2025)

Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Yazar:: Andrew O. Yam (15293045)
Baskı/Yayın Bilgisi: (2025)

Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Yazar:: Andrew O. Yam (15293045)
Baskı/Yayın Bilgisi: (2025)

Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Yazar:: Andrew O. Yam (15293045)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_qu50atjsnebr8uf2m4aus0hnc6